Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
10-2019

Evaluation of intervention aimed at reducing alteplase returns
without compromising clinical care in acute ischemic stroke
Natalie Swearingen
Jillian Myers
Alyx Lesko
Lindsay Lucas
Elizabeth Baraban

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Neurology Commons, and the Nursing Commons

Evaluation of Intervention Aimed at Reducing Alteplase Returns
Without Compromising Clinical Care in Acute Ischemic Stroke
Natalie Swearingen, MSN, RN, CNRN, Jillian Myers PharmD, BCPS, Alexandra Lesko, Lindsay Lucas, MS & Elizabeth Baraban, MPH, PhD

Background / Objective
• In 2010, the AHA/ASA’s Target Stroke best practice recommendations to reduce door to needle times
(DTN) included early pre-mix of intravenous alteplase.
• Early premixing of alteplase has led to unused vials. The price for replacement vials range from $6,400 to
$8,400 per 100mg vial. However, hospitals have largely recouped the cost of wasted alteplase by
returning them to the drug manufacture for free replacement vials.
• Our Primary Stroke Center (PSC) had a high return rate prompting our team to implement interventions
aimed at ethical stewardship of resources without compromising clinical care.
• Objective: Evaluate whether specific interventions reduced clinical expenses without affecting timeliness
of clinical care at our PSC

Methods
• The following intervention was implemented between July–Sept 2015:
o Establishing a dedicated pharmacist in the ED to mix alteplase at bedside Friday–Tuesday, 12:30–21:00,
in addition to existing satellite pharmacy available all other times
o Implementing single call number from neurology to pharmacist to initiate treatment
o Educating neurologist on current alteplase waste and cost per vial
• Clinical data were from the American Stroke Association’s Get with the Guidelines database; alteplase vial
usage was from the pharmacy’s internal quality tracking database
• Data from Acute Ischemic Stroke (AIS) patients presenting at our PSC emergency room within 4.5 hours of
Last Known Well (LKW) and treated with IV-alteplase between Jan–June 2015 & Sept–Nov 2016 were
included
• Exclusions: inpatient strokes or those with diagnoses unrelated to stroke; alteplase mixes during the
implementation phase (July–August, 2015)
• Pre-intervention cases (Jan–June 2015) were compared to post-intervention cases (Sept 2015–Nov 2016)
• Primary outcomes:
o Change in % returned vials (total vials returned/total vials mixed) between pre- and post-intervention time
periods
o Expected number of post-intervention vials that would have been returned using pre-intervention percent
returned was calculated to assess costs
o Costs were derived using the number of expected returned vials vs actual number of returned vials (cost =
# of vials * cost/vial). Costs were estimated as a range between $6400–$8400 per returned 100mg vial.
Cost Savings = ‘expected’ minus ‘actual’ returns for the post-intervention time period
• Secondary outcomes: median DTN and median pharmacy go-ahead call time to needle time (GoTN); MannWhitney test was used to compare DTN and GoTN between pre and post- intervention time periods
• A sub-analysis of patients treated during the post-intervention time period was used to determine whether
GoTN or DTN differed depending on location of alteplase mixing (satellite pharmacy vs ED bedside); Mann
Whitney tests were used to determine differences.

Results
• Data from 126 alteplase administered AIS patients were included
• Pre-intervention alteplase returns was 39.5% (15/38) versus 11.3%
(10/88) post-intervention (Table 1)
• Post-intervention, the observed number of returned vials was lower
than expected (10 vs 35) (Table 1)
• Pre-intervention expected cost of returned vials ranged from
$96,000–$126,000, post-intervention expected cost was $76,800–
$100,800, equaling cost-savings of $166,400–$218,400 (Table 1)

• DTN was not significantly different post- vs pre-intervention (median
[IQR]=51.0 min [36.8,68.0] vs 52.0 min [40.0,68.0]; p=0.966) (Figure 1).
• GoTN was significantly faster post- vs pre-intervention (median
[IQR]=10.0 min. [8.0,14.8] vs 16.0 min. [11.5,19.5]; p=.011) (Figure 1).
• Sub-analysis among post-intervention cases found that DTN and GoTN
were not significantly different when pharmacy mixed alteplase in the ED
compared to the satellite pharmacy (median DTN [IQR]=45.0 min [35.0,
68.0] vs. 53.0 min [42.0, 68.0]; p=0.701) & median GoTN [IQR]=8.00 min
[6.0, 13.0] vs. 11.00 min [9.0,14.75], respectively.

Table 1. Cost Savings in the Post-Intervention Time Period.
a

Calculation based
on 88 postintervention mixes.
b Actual number of
mixes returned in
post-intervention
time period.
c Minimum Cost =
number of mixes
returned*minimum
cost per mix,
$6,400/vial
d Maximum Cost =
number of mixes
returned*maximum
cost per mix,
$8,400/vial

Figure 1. Decrease in GoTN Times from Pre to PostIntervention while DTN Times Remained the Same.

Conclusions

References

• Percentage of vials returned decreased substantially following the intervention and
resulted in extensive cost savings
• PSCs can reduce overall waste of alteplase and decrease costs without negatively
effecting clinical care
• Stroke programs need to stay aware of both the increasing costs of alteplase and
changes in replacement policies, including the November 2016 change from 6 months to
30 days with a physician or pharmacy director signature required for reimbursement
• Continued research is needed to assess the impact of other interventions aimed at
reducing DTN times in the ED and its effect on alteplase waste
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